II. Indications
- Renal Transplant Rejection Prophylaxis
- Basiliximab (Simulect)
- Used in combination with Cyclosporine and Corticosteroids
- Daclizumab (off-market, see below)
- Basiliximab (Simulect)
-
Multiple Sclerosis
- Daclizumab (off-market, marginal efficacy, see below)
III. Mechanism
- Interleukin-2 Receptor Alpha (IL-2Ra, CD25)
- Interleukin 2 binds IL-2Ra on Leukocyte surface, triggering immune response
- IL-2Ra binding is involved in cell signaling, immune response, cell proliferation and apoptosis
- IL-2Ra (CD25) is expressed on the surface of Leukocytes, esp. activated T Cells and Regulatory T Cells (Tregs)
- Alpha subunit combines with 2 other subunits (beta and gamma chain) to form a high affinity Interleukin 2 receptor
- Interleukin 2 binds IL-2Ra on Leukocyte surface, triggering immune response
- CD25 Monoclonal Antibody
- Chimeric monoclonal antibodies bind CD25 receptor alpha on Leukocytes (esp. activated T Cells)
- Blocks Interleukin-2 binding, thereby reducing IL-2 mediated immune response
IV. Dosing
- See other references for disease specific dosing protocols
- Prescribers are typically specialists knowledgeable about the risks and monitoring of Voclosporin
V. Medications
- Basiliximab (Simulect)
- Daclizumab (Zinbryta, off-market)
- https://www.fda.gov/drugs/drug-safety-and-availability/fda-working-manufacturers-withdraw-zinbryta-market-united-states
- Voluntarily removed from market 2018 after association with autoimmune Encephalitis, and risk of hepatotoxicity
VI. Adverse Effects: Basiliximab
- Severe acute Hypersensitivity Reaction (including Anaphylaxis)
- Cytokine Release Syndrome
- Gastrointestinal
- Cardiovascular
- Febrile Illness
- Metabolic
- Electrolytes
- Neurologic
- Hematologic
VII. Safety: Basiliximab
- Unknown safety in Lactation
- Unknown safety in pregnancy (although labeled as Pregnancy Category B)
- Use only in pregnancy if benefit outweighs risk
VIII. Resources
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI) | A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. |
Definition (NCI_NCI-GLOSS) | A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count). |
Definition (PDQ) | A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42006&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42006&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1569" NCI Thesaurus) |
Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) |
MSH | C096001 |
SnomedCT | 109133001, 386977009 |
English | Dacliximab, Anti-Tac Humanized Monoclonal Antibody, humanized anti-Tac monoclonal antibody, monoclonal antibody anti-Tac, monoclonal antibody humanized anti-Tac, Daclizumab, daclizumab, daclizumab [Chemical/Ingredient], anti-tac, Immunoglobulin G 1, (human-mouse monoclonal 1H4 gamma-chain, anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer, dacliximab, Daclizumab (product), Daclizumab (substance), anti-Tac, anti-Tac monoclonal antibody, MOAB anti-Tac, Humanized Anti-Tac Monoclonal Antibody, Monoclonal Antibody Anti-Tac, Anti-Tac Monoclonal Antibody, Anti-Tac, DACLIZUMAB |
Spanish | daclizumab (producto), daclizumab (sustancia), daclizumab |
Ontology: basiliximab (C0676831)
Definition (NCI) | A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. |
Definition (PDQ) | A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459956&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459956&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52186" NCI Thesaurus) |
Concepts | Immunologic Factor (T129) , Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) |
MSH | C113157 |
SnomedCT | 109135008, 386978004 |
English | basiliximab, basiliximab (Simulect), basiliximab (medication), BASILIXIMAB, basiliximab [Chemical/Ingredient], Basiliximab, Basiliximab (product), Basiliximab (substance), Basilixumab |
Spanish | basilixmab (producto), basilixmab (sustancia), basilixmab |
Ontology: Interleukin 2 Receptor, Alpha (C1101536)
Definition (NCI) | Interleukin-2 receptor alpha chain (272 aa, 31 kD) is a cell fate protein that is encoded by the human IL2RA gene and has roles in immune response, cell proliferation, apoptosis and signal transduction. |
Definition (MSH) | A low affinity interleukin-2 receptor subunit that combines with the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN to form a high affinity receptor for INTERLEUKIN-2. |
Concepts | Receptor (T192) , Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129) |
MSH | D053645 |
English | Antigens, CD25, CD25 Antigens, Tac P55 Peptide, CD25 Antigen, IL-2Ralpha, Antigen, CD25, IL 2Ralpha, Interleukin 2 Receptor alpha Chain, Interleukin 2 Receptor alpha Subunit, Interleukin 2 Receptor alpha, Interleukin 2 Receptors alpha, Interleukin 2Ralpha, Interleukin-2 Receptor alpha Chain, Interleukin-2 Receptor alpha Subunit, Interleukin-2 Receptor alpha, Interleukin-2 Receptors alpha, Interleukin-2Ralpha, Receptor alpha, Interleukin-2, Receptors alpha, Interleukin-2, alpha-subunit, Receptor, Interleukin-2, TAC PEPTIDE P 055, INTERLEUKIN 002 RECEPTOR ALPHA SUBUNIT, CD 025 ANTIGENS, ANTIGENS CD 025, INTERLEUKIN 002 RECEPTORS ALPHA, Interleukin-2 Receptor Alpha Chain, Interleukin-2 Receptor alpha Subunit [Chemical/Ingredient], Interleukin 2 Receptor, Alpha, IL-2 Receptor, Interleukin 2 Receptor, CD25, IL-2R, IL2R, IL2RA, Low Affinity Interleukin 2 Receptor |
Portuguese | Receptores de Interleucina-2, Subunidade alfa, Subunidade alfa de Receptor de Interleucina-2, Peptídeo Tac P55, Antígenos CD25, Subunidade alfa de Receptor da Interleucina-2, Subunidade alfa do Receptor da Interleucina-2, Subunidade alfa de Receptores da Interleucina-2, Receptores alfa de Interleucina-2 |
Spanish | Subunidad alfa del Receptor de Interleucina-2, Receptores de Interleucina-2, Subunidad alfa, Antígenos CD25, Péptido Tac P55, Receptores alfa de Interleucina-2 |
Russian | TAC P55 ПЕПТИД, ИНТЕРЛЕЙКИНА-2 РЕЦЕПТОРЫ АЛЬФА, ИНТЕРЛЕЙКИНА-2 РЕЦЕПТОРА АЛЬФА-СУБЪЕДИНИЦА, АНТИГЕНЫ CD25, РЕЦЕПТОРЫ АЛЬФА ИНТЕРЛЕЙКИНА-2, TAC P55 PEPTID, INTERLEIKINA-2 RETSEPTORA AL'FA-SUB"EDINITSA, INTERLEIKINA-2 RETSEPTORY AL'FA, RETSEPTORY AL'FA INTERLEIKINA-2, ANTIGENY CD25 |
German | Interleukin-2-Rezeptor-alpha, Interleukin-2-Rezeptor, alpha-Untereinheit, CD25-Antigen, Interleukin-2-Rezeptoren, alpha, IL-2Ralpha, Interleukin-2Ralpha, CD25-Antigene, Interleukin-2-Rezeptor, alpha-Kette, Interleukin-2-Rezeptor, alpha-chain, Tac-P55, Peptide |
French | Peptide Tac, Chaîne alpha du récepteur à l'interleukine-2, Chaîne alpha du récepteur de l'interleukine-2, Antigène CD25, Chaîne alpha du récepteur à l'IL-2, Sous-unité alpha du récepteur à l'IL2, Sous-unité alpha du récepteur à l'IL-2, Peptide p55, Sous-unité alpha du récepteur à l'interleukine-2, IL-2-R alpha, Sous-unité alpha du récepteur de l'interleukine-2, Antigènes CD25, CD25 |
Finnish | Interleukiini-2-reseptorin alfa-alayksikkö |
Czech | IL-2Ralfa, antigen CD25, antigeny CD25, peptid Tac P55, receptor pro interleukin-2 - alfa-podjednotka, interleukin-2 - receptor alfa, receptor interleukinu-2 - alfa-podjednotka |
Italian | Sottounità alfa del recettore per l'interleuchina-2 |
Swedish | Interleukin-2 Receptor alpha Subunit |
Polish | Podjednostka alfa receptora interleukiny 2 |
Japanese | インターロイキン2受容体アルファサブユニット, インターロイキン2受容体αサブユニット, インターロイキン2受容体アルファ, 抗原-CD25, TACペプチド, Tac抗原, インターロイキン-2受容体アルファ, TAC p55ペプチド, CD25抗原 |
Ontology: Anti-CD25 Monoclonal Antibody (C2698127)
Definition (NCI) | Any monoclonal antibody directed against the alpha subunit of the human interleukin 2 receptor. |
Concepts | Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129) , Pharmacologic Substance (T121) |
English | Anti-CD25 Monoclonal Antibody |